New England Journal of Medicine Study Reports Xpert MTB/RIF a Faster, More Sensitive & Specific Test for Tuberculosis (TB) Than Current World Standards
SUNNYVALE, Calif., Sept. 2 /PRNewswire-FirstCall/ — Cepheid (Nasdaq: CPHD) today announced that its XpertÃ‚® MTB/RIF test was the subject of a study published in the latest edition of the New England Journal of Medicine (NEJM), “Rapid Molecular Detection of Tuberculosis and Rifampin Resistance.” The complete study is now available online (http://www.nejm.org) and will appear in the September 9 print edition.
Funded and led by the Foundation for Innovative New Diagnostics (FIND), the study compared the sensitivity and specificity of Xpert MTB/RIF to the best available reference standards in the diagnosis of 1,730 patients with suspected drug-sensitive or multi drug-resistant pulmonary tuberculosis (TB) at five centers in Peru, Azerbaijan, South Africa, and India. The study concluded that Cepheid’s Xpert MTB/RIF – an easy-to-use molecular test developed in partnership with FIND and the University of Medicine and Dentistry of New Jersey (UMDNJ), with additional funding from the National Institute of Allergy & Infectious Diseases (NIAID) – provided sensitive and specific detection of tuberculosis and rifampin resistance (a critical marker of multidrug resistance) directly from untreated sputum specimens in less than two hours.
“One of FIND’s primary goals is to help save the millions of lives needlessly lost to TB every year,” said Giorgio Roscigno, chief executive officer of FIND. “Early, rapid and accurate detection of TB, including identification of drug-resistant strains, is critical to effectively treating the disease, reducing secondary resistance, stopping further transmission and saving lives. Cepheid’s commitment to researching and bringing this test to market has been outstanding. This study demonstrates that Xpert MTB/RIF delivers a quantum leap in patient management to the developing world, where it is most needed. We are proud to be a part of this landmark project.”
Designed for use on Cepheid’s GeneXpertÃ‚® Systems, Xpert MTB/RIF not only detects the presence of TB, but also identifies whether it is resistant to rifampin, a critical first-line drug for treatment of the disease and a reliable surrogate marker of strains that are multidrug-resistant (MDR-TB). The CE-IVD test is enabling physicians outside of the U.S. to dramatically improve patient outcomes through rapid, actionable results that guide therapy decisions within the timeframe of an initial patient visit.
“The need for accurate and rapid detection of tuberculosis for the growing at-risk populations in the developing world has been well documented,” said John Bishop, Cepheid’s chief executive officer. “The GeneXpert System has a unique level of technical capability – no other molecular system could have enabled a TB test as accurate, fast, and easy-to-use as Xpert MTB/RIF. Clinicians are now able to obtain dependable test results for not only detection of TB, but also simultaneous determination of whether or not it is a drug resistant strain in virtually any clinical setting.”
Rapid diagnosis of TB is vital in areas such as sub-Saharan Africa and Southeast Asia due to the close connection between HIV and TB. The most commonly used diagnostic tool in many settings is still sputum microscopy, which often delivers poor sensitivity in patients suffering from TB, delaying accurate diagnosis and treatment until culture and sensitivity testing are completed weeks later. In fact, sputum microscopy has very poor sensitivity in those who also have HIV co-infection. The weakened immune system of an HIV-positive person is particularly susceptible to infection, resulting in one third of the 33 million HIV sufferers worldwide infected with TB. Left undetected and untreated, 90 percent of these people will die within months of first contracting the disease, reinforcing the urgent need for a solution.
“The Xpert MTB/RIF test is the most technologically advanced test for TB ever developed, yet it is simple enough to perform in all corners of the world, including in resource-limited settings where it is most needed,” said David H. Persing, M.D., Ph.D., Cepheid’s chief medical and technology officer. “Determining simultaneously the presence of TB and drug resistance helps to eliminate guesswork and provides maximum medical value in the management of TB cases worldwide.”
The NEJM study found that with a single, untreated sample Xpert MTB/RIF was 98.2 percent sensitive in patients with smear-positive (test by sputum microscopy), culture-positive TB, 99.2 percent specific in patients without TB, and 97.6 percent sensitive in patients with rifampin resistance. Further, when testing smear-negative, culture-positive samples, Xpert MTB/RIF was 90.2 percent sensitive when compared to the standard analysis of three sputum samples by microscopy and was 72.5 percent positive on a single sample.
“We designed this test so that it could be used by someone with minimal training,” said UMDNJ’s David Alland, M.D, who collaborated closely with Cepheid and FIND with support from the NIAID. “We’re gratified to find that it requires less hands-on work than the acid fast smear, long considered the standard method to identify TB, and yet is much more sensitive.”
Xpert MTB/RIF is currently available outside the U.S., marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. It is currently expected to become available in the U.S. within the 2012-2013 timeframe.
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com .
FIND is a non-profit Swiss organization established in 2003, with offices in Switzerland, Uganda and India. Its mission is to develop, evaluate, demonstrate, and accelerate the roll out of new diagnostic tests and platforms for diseases of poverty, including TB, malaria and human African trypanosomiasis. FIND’s approach is to address diagnostic needs across disease areas so that tests can also be implemented at levels of the health care system closer to where patients first seek care. FIND has active collaborations with over 100 partners, including Ministries of Health, bilateral and multilateral organizations, such as WHO, research institutes/academia, commercial partners and clinical trial sites.
In addition to its contribution to diagnostic advances for TB (with four diagnostic tools endorsed by WHO into global policy since 2007), and malaria (with the completion of the first-ever product testing program for rapid diagnostic tests), FIND has a significant program targeted at neglected diseases. Current donors include the Bill & Melinda Gates Foundation, Government of the Netherlands, the European Union, UNITAID, UK Department for International Development, National Institutes of Health (USA) and others. FIND is ISO 9001:2008 and ISO 13485:2003 certified. For more information, please visit: http://www.finddiagnostics.org/.
This press release contains forward-looking statements that are not purely historical regarding Cepheid’s or its management’s intentions, beliefs, expectations and strategies for the future, including those relating to product performance, future market opportunities and product release dates. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company’s current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen manufacturing problems; regulatory developments and practices regarding testing; unforeseen delays in product development and commercialization activities; customer and market acceptance of the product; the failure of products to perform as fast or as accurately as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; and underlying market conditions worldwide. Readers should also refer to the section entitled “Risk Factors” in Cepheid’s Annual Report on Form 10-K for 2009 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.
CONTACTS: At Cepheid For Cepheid Investor For Media Inquiries: Inquiries: -------------------- -------------------- Jared Tipton Jacquie Ross Cepheid Corporate Communications Cepheid Investor Relations 408-400-8377 408-400-8329 firstname.lastname@example.org email@example.com
CONTACTS: At FIND For Media Inquiries: -------------------- Lakshmi Sundaram Advocacy Officer +41-79-935-6419 Lakshmi.firstname.lastname@example.org Or Beatrice Gordis Communications Officer +41-22-710-9310 Beatrice.email@example.com
SOURCE Cepheid; FIND